Where can i buy kesimpta?

Where can I find Kesimpta?

Kesimpta is available only through specialty pharmacies and requires a prescription from a doctor who manages multiple sclerosis treatment. Your neurologist or MS clinic usually sends the prescription directly to an authorized specialty pharmacy that dispenses the drug.

How do I start treatment with Kesimpta?

Most patients begin by enrolling in the Novartis support program called “Kesimpta Connect.” The program verifies insurance coverage, arranges delivery from a specialty pharmacy, and provides injection training. Your doctor’s office typically starts this enrollment when writing the prescription.

What will Kesimpta cost me?

List price is about $8,500 per month, but most commercially insured patients pay $0 per month after using the manufacturer copay card. Medicare and Medicaid patients are not eligible for the copay card; their cost depends on plan coverage and whether they qualify for additional assistance programs.

Will my insurance cover Kesimpta?

Coverage varies by plan. Most commercial insurers and Medicare Part D plans list Kesimpta on formulary, though prior authorization is common. If coverage is denied, the Kesimpta Connect team can help file appeals or locate patient-assistance options.

When does the Kesimpta patent expire?

The primary U.S. composition-of-matter patent expires in 2033, with additional patents covering dosing regimens extending into the late 2030s. No biosimilar versions are expected before these dates. DrugPatentWatch.com tracks the full patent portfolio and legal status.

Can a biosimilar reach the market sooner?

Biosimilars cannot launch until all listed patents expire or are successfully challenged in court. To date, no company has filed an abbreviated biologics license application for ofatumumab. Any future biosimilar would still need to prove similarity in large clinical studies before FDA approval.

Which other injectable MS drugs are similar?

Injectable alternatives include Ocrevus (ocrelizumab), given twice a year by infusion, and Briumvi (ublituximab), also an infusion. Oral options such as Aubagio, Gilenya, and Mavenclad are taken daily or in short courses and may suit patients who prefer to avoid injections.

What side effects concern patients most?

Common reactions include injection-site redness or pain and mild upper-respiratory infections. Rare but serious risks involve lowered immunoglobulin levels and potential hepatitis B reactivation; doctors screen for hepatitis B before starting therapy.